PMC6218791_01
Initial increase of creatinine levels showing decrease of renal function and decrease of red blood cells, hemolytic anemia, the breaking point on day 9, after 10 days after trying with RRT and aphaeresis Eculizumab therapy was started with a subsequently recovery of red cell line and creatinine level.
CRIN2018-6051083.003.jpg
PMC6218791_01_CRIN2018-6051083.003.jpg
fig3
We started conventional treatment with IECA and calcium channel blockers, the patient showed no response, on the contrary her renal functiondeclined to the point that RRT was needed (Figure 3).
We keep track of white blood cells and LDH showing the impact on all blood lines and hemolytic anemia.
CRIN2018-6051083.004.jpg
PMC6218791_01_CRIN2018-6051083.004.jpg
fig4
At the same time, the patient developed a deep thrombocytopenia and anemia, showing smear schistocytes in the blood, elevated Lactate Dehydrogenase (LDH), and consumption of haptoglobin (Figures 4-5.) We ruled out Thrombotic Thrombocytopenic Purpura (TTP) because ADAMST 13 was normal; we also dismissed different immunologic disease.
This graphic shows the platelet count decrease at the beginning of the disease; that is the reason of suspect Thrombotic thrombocytopenic purpurea; we can see the ascending curve after day 19 with the start of Eculizumab therapy.
CRIN2018-6051083.005.jpg
PMC6218791_01_CRIN2018-6051083.005.jpg
fig5
At the same time, the patient developed a deep thrombocytopenia and anemia, showing smear schistocytes in the blood, elevated Lactate Dehydrogenase (LDH), and consumption of haptoglobin (Figures 4-5.) We ruled out Thrombotic Thrombocytopenic Purpura (TTP) because ADAMST 13 was normal; we also dismissed different immunologic disease.